Cancer Research UK scientists have discovered how giving a class of drugs called AKT inhibitors in combination with radiotherapy might boost its effectiveness across a wide range of cancers, according to a study published in the Journal of Clinical Investigation today*.
Tumours often grow so quickly that some of the cells do not have access to the body's blood supply, causing them to become oxygen-starved. This rapid growth usually sends signals to the cells to die, but in cancers with faults in a gene called p53 -- present in at least half of all cancers -- this signal is blocked meaning the cells carry on growing.
In this study, the researchers found that six genes that help protect the body against cancer were less active in oxygen-starved cancer cells when p53 was also faulty.
In the absence of two of these genes -- PHLDA3 and INPP5D -- a gene called AKT becomes permanently switched on preventing the cells from dying despite being oxygen-starved.
When drugs designed to block AKT were given to mice with tumours and lab-grown cancer cells lacking p53, the radiotherapy killed more tumour cells.
Importantly, lower activity in these genes was also linked to poorer survival in patients with a variety of different cancers. This suggests that adding AKT inhibitors to radiotherapy could be an effective way to treat many cancers.
Study leader Dr. Ester Hammond, a Cancer Research UK scientist at the University of Oxford, said, 'this exciting discovery sheds light on the role of oxygen starvation in cancer development and suggests that drugs already being trialled in cancer patients could potentially boost the effectiveness of radiotherapy across a range of cancers. We hope that this important piece of the jigsaw will support ongoing efforts to develop drugs that enhance radiotherapy, so that even more patients can benefit from this cornerstone of cancer treatment.'
Eleanor Barrie, Cancer Research UK's senior science information manager, said, 'advances in how we give radiotherapy and use it in combination with other treatments have the potential to improve survival for thousands of cancer patients. More than half of all cancer patients receive radiotherapy as part of their treatment, so anything that can be done to improve its effectiveness is potentially great news for patients.'
Contact? the Cancer Research UK press office on 020 3469 8300 or, out of hours, on 07050 264 059.
Leszczynska et al, Hypoxia-induced p53 modulates both apoptosis and radiosensitivity via AKT, J Clin Invest (2015), doi:10.1172/JCI80402
Online at: http://www.
About Cancer Research UK
- Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research
- Cancer Research UK's pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives
- Cancer Research UK receives no government funding for its life-saving research. Every step it makes towards beating cancer relies on every pound donated
- Cancer Research UK has been at the heart of the progress that has already seen survival rates in the UK double in the last 40 years
- Today, two in four people survive cancer for at least 10 years. Cancer Research UK's ambition is to accelerate progress so that three in four people will survive cancer within the next 20 years
- Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses
- Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured